Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 17Gastrointestinal 5CNS 4Thoracic 3Other solid neoplasm 3Plasma cell 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 630Triple Negative Breast Neoplasms 166Ovarian Neoplasms 103Carcinoma, Non-Small-Cell Lung 100Neoplasm Metastasis 76Colorectal Neoplasms 64Melanoma 61Stomach Neoplasms 60Neoplasms 56Pancreatic Neoplasms 55Squamous Cell Carcinoma of Head and Neck 50Prostatic Neoplasms 48Endometrial Neoplasms 48Lung Neoplasms 47Uterine Cervical Neoplasms 36Carcinoma, Renal Cell 35Sarcoma 33Head and Neck Neoplasms 33Esophageal Neoplasms 32Breast Neoplasms, Male 29Urinary Bladder Neoplasms 26Small Cell Lung Carcinoma 26Colonic Neoplasms 26Carcinoma, Transitional Cell 23Carcinoma, Ovarian Epithelial 21Lymphoma 18Brain Neoplasms 18Kidney Neoplasms 17Carcinoma, Hepatocellular 17Liver Neoplasms 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neurofibrosarcoma × Breast × Clear all
NCT06603987 2025-11-19

Using CICS-1 and SPM-011 and ï¼»18Fï¼½FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA

Stella Pharma Corporation

Phase 1/2 Enrolling by invitation
30 enrolled
BreastGastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡